Dr. Grace Wright, Rheumatologist

Paid consultant to GSK at the time of filming.


    DR. WRIGHT: I’m Doctor Grace Wright, a Rheumatologist in New York City.

    ON-SCREEN TEXT: Dr. Grace Wright, Rheumatologist
    Paid consultant to GSK at the time of filming.


    DR. WRIGHT: So, if my peer were to ask me, “Why should I use BENLYSTA? Why should I use it earlier?”, I think back to the fact that our patients are living with a chronic disease – one that they will experience over the course of their lifetime – and if we can initiate therapy that can help to control that disease activity earlier, then I think that’s a good thing to do.

    ON-SCREEN TEXT: “Help control disease activity”

    DR. WRIGHT: When we look at the data, we now have years of data on efficacy, on safety. We have clinical trial data, we have real-world data, the kinds of data that we need to have a discussion with our patients about how this can work for them.

    ON-SCREEN TEXT: Years of data on BENLYSTA

    DR. WRIGHT: And so, if we just think through the data, and think about the impact that we can have on controlling disease activity, it just feels like the right thing to do to help our patients manage something that they have to live with for the rest of their lives.

    ON-SCREEN TEXT: “Help our patients”

    DR. WRIGHT: And so, I think it’s really important to put everything into context about that patient and what they experience and how we can help them improve their disease control.

    DR. WRIGHT: Thank you for watching. Visit the BENLYSTA website for more information.

    BENLYSTA is indicated for patients aged ≥5 with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard therapy and patients aged ≥18 with active lupus nephritis receiving standard therapy. BENLYSTA is not recommended in patients with severe active central nervous system lupus or in combination with other biologics.



    Previous anaphylaxis with BENLYSTA.


    Serious Infections: Serious and sometimes fatal infections have been reported and occurred more frequently with BENLYSTA. Use caution in patients with severe or chronic infections, and consider interrupting therapy in patients with a new infection.

    Progressive Multifocal Leukoencephalopathy (PML): Cases of JC virus-associated PML resulting in neurological deficits, including fatal cases, have been reported. If PML is confirmed, consider stopping immunosuppressant therapy, including BENLYSTA.

    Please see additional Important Safety Information and full Prescribing Information, including Medication Guide, on the BENLYSTAHCP.com website.

    Intravenous Use 120 mg/vial
    Subcutaneous Use 200 mg/mL

    GSK Logo

    Trademarks are owned by or licensed to the GSK group of companies. | ©2021 GSK or licensor. BELVID210038 November 2021. Produced in USA.

You may also like


Dr. William Pendergraft, Nephrologist


Dr. Alvin Wells, Rheumatologist

Paid consultants to GSK at the time of filming.